tetano
Editor, Senior Moderator
J Med Virol
. 2022 Aug 5.
doi: 10.1002/jmv.28049. Online ahead of print.
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants
Lirong Zou[SUP] 1 [/SUP], Huan Zhang[SUP] 1 [/SUP], Zhonghua Zheng[SUP] 1 [/SUP], Yushan Jiang[SUP] 2 [/SUP], Yushi Huang[SUP] 1 [/SUP], Shujian Lin[SUP] 1 [/SUP], Jianxiang Yu[SUP] 1 [/SUP], Xiaoling Deng[SUP] 1 [/SUP], Jianfeng He[SUP] 1 [/SUP], Chenguang Shen[SUP] 1 [/SUP], Baisheng Li[SUP] 1 [/SUP]
Affiliations
Abstract
Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been emerging and circulating in different parts of the world. Millions of vaccine doses have been administered globally, which reduces the morbidity and mortality of COVID-19 efficiently. Here we assess the immune responses of individuals after two shots of BBIBP-CorV or CoronaVac inactivated vaccine. We measured neutralizing antibody responses after the second vaccination using authentic SARS-CoV-2 and its viral variants. All the serum samples efficiently neutralized wild-type SARS-CoV-2 wild-type lineage, in contrast, a part of serum samples failed to neutralize Alpha, Beta, Gamma, Delta or Eta lineages, and only several serum samples were able to neutralize Omicron lineage virus strains (BA.1 and BA.2) with low neutralization titer. As compared with neutralization of SARS-CoV-2 wild-type lineage, neutralization of all other SARS-CoV-2 variant lineages was significantly lower. Considering that all the SARS-CoV-2 mutation viruses challenged the antibody neutralization induced by BBIBP-CorV and CoronaVac, it is necessary to carry out a third booster vaccination to increase the humoral immune response against the SARS-CoV-2 mutation viruses. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2; immune response; inactivated vaccine; neutralizing antibodies; viral variants.
. 2022 Aug 5.
doi: 10.1002/jmv.28049. Online ahead of print.
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants
Lirong Zou[SUP] 1 [/SUP], Huan Zhang[SUP] 1 [/SUP], Zhonghua Zheng[SUP] 1 [/SUP], Yushan Jiang[SUP] 2 [/SUP], Yushi Huang[SUP] 1 [/SUP], Shujian Lin[SUP] 1 [/SUP], Jianxiang Yu[SUP] 1 [/SUP], Xiaoling Deng[SUP] 1 [/SUP], Jianfeng He[SUP] 1 [/SUP], Chenguang Shen[SUP] 1 [/SUP], Baisheng Li[SUP] 1 [/SUP]
Affiliations
- PMID: 35931461
- DOI: 10.1002/jmv.28049
Abstract
Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been emerging and circulating in different parts of the world. Millions of vaccine doses have been administered globally, which reduces the morbidity and mortality of COVID-19 efficiently. Here we assess the immune responses of individuals after two shots of BBIBP-CorV or CoronaVac inactivated vaccine. We measured neutralizing antibody responses after the second vaccination using authentic SARS-CoV-2 and its viral variants. All the serum samples efficiently neutralized wild-type SARS-CoV-2 wild-type lineage, in contrast, a part of serum samples failed to neutralize Alpha, Beta, Gamma, Delta or Eta lineages, and only several serum samples were able to neutralize Omicron lineage virus strains (BA.1 and BA.2) with low neutralization titer. As compared with neutralization of SARS-CoV-2 wild-type lineage, neutralization of all other SARS-CoV-2 variant lineages was significantly lower. Considering that all the SARS-CoV-2 mutation viruses challenged the antibody neutralization induced by BBIBP-CorV and CoronaVac, it is necessary to carry out a third booster vaccination to increase the humoral immune response against the SARS-CoV-2 mutation viruses. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2; immune response; inactivated vaccine; neutralizing antibodies; viral variants.